100,000 patients in the U.S. have ascites due to advanced liver cirrhosis, with no approved drug to treat ascites. Jonathan Adams, CEO & CFO of BioVie Inc. (OTCQB: BIVI) discusses how the company is developing what they hope to be the first ever approved drug to treat ascites.

While in LA for the latest LD Micro conference, we had chance to speak with William Waldrop, CEO of Signal Bay, Inc. (OTCQB: SGBY) which owns Signal Bay Research, Signal Bay Services and EVIO labs. Listen in to learn more about the latest developments in research, consulting and testing services for the legal cannabis industry.